Last reviewed · How we verify

NCT03686085

Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.

Completed Phase 3 Last updated 30 June 2020
What this trial tests

Phase 3 trial testing Dinoprostone 3 mg in Intrauterine Device in 200 participants. Completed in 10 March 2019.

Timeline
30 September 2018
Primary endpoint
1 March 2019
10 March 2019

Quick facts

Lead sponsorCairo University
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment200
Start date30 September 2018
Primary completion1 March 2019
Estimated completion10 March 2019
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

18 and older, female only, with Intrauterine Device. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate whether vaginal dinoprostone administered before intrauterine device (IUD) insertion reduces failed insertions, insertion-related complications and pain in nulliparous women.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dinoprostone 3 mg

Trials testing the same drug.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03686085.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing